Improving patient access to life-enhancing medications
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals.
We have a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world.
We offer patients better, safer & more accessible medicines.
To improve patient access to life-enhancing prescription medications, Mayne Pharma offers a robust portfolio of branded and generic drugs in multiple therapeutic areas, including women's health, oncology, dermatology and cardiology.
Mayne Pharma has a full service contract development and manufacturing organisations (CDMO) specialising in novel oral and topical dose forms providing pharmaceutical development, analytical testing and commercial manufacturing to clients worldwide. Our mission is to partner with clients to develop and deliver pharmaceutical products from “concept to commercialisation” to change the lives of patients around the globe:
At Mayne Pharma, we recognise that we are part of a global community. As part of this community, we are committed to operating our business in a sustainable manner. We ensure our people are safe and well-supported, local communities prosper and the environment is well cared for so that it benefits future generations.
For investorsMore for investors
News & Events
Mayne Pharma to return up to $113m to shareholders
28 Oct 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that following completion of the sale of Metrics Contract Services (Metrics) it intends to return up to $113 million to shareholders, through a combination of cash distributions.
Mayne Pharma completes sale of Metrics Contract Services
4 Oct 2022
Mayne Pharma Group Limited is pleased to announce the completion of the sale of Metrics Contract Services (Metrics) to Catalent Pharma Solutions, Inc. for US$475 million (approximately A$722 million at current exchange rates).
Mayne Pharma appoints new CEO
28 Sep 2022
Mayne Pharma Group Limited is pleased to announce it has appointed Mr Shawn Patrick O’Brien as Chief Executive Officer and Managing Director effective 1 October 2022. This follows from the previously announced retirement of Mr Scott Richards and a comprehensive search for a successor.
Non Executive Director appointment and retirement
31 Aug 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr David Petrie, has accepted an invitation to join the Board of Mayne Pharma, effective 1 September 2022.
Mayne Pharma 2022 Full Year Results Media Release
26 Aug 2022
Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, we reported annual revenue growth for the first time in five years. Excluding retail generics, the remaining businesses which represent more than 80% of reported gross profit grew 27% on the prior corresponding period (pcp).
Mayne Pharma CEO announces plan to retire
19 Aug 2022
Mayne Pharma Group Limited advises that Chief Executive Officer (CEO) Scott Richards has announced his intention to retire following a decision by the Board to relocate the CEO role to the US on a permanent basis. Mr Richards is unable to make this commitment and wants to return to Australia for personal reasons.